.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
US Army
Federal Trade Commission
UBS
Julphar
Chinese Patent Office
Deloitte
Harvard Business School
Novartis

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,849,911

« Back to Dashboard

Which drugs does patent 5,849,911 protect, and when does it expire?


Patent 5,849,911 protects REYATAZ and EVOTAZ and is included in three NDAs. There have been three Paragraph IV challenges on Reyataz.

Protection for REYATAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in twenty-nine countries.

Summary for Patent: 5,849,911

Title: Antivirally active heterocyclic azahexane derivatives
Abstract:There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl, R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl, R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl, R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl, R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and R.sub.6, independently of R.sub.1, is lower alkoxycarbonyl, or salts thereof, provided that at least one salt-forming group is present. The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.
Inventor(s): Fassler; Alexander (Macclesfield, GB3), Bold; Guido (Gipf-Oberfrick, CH), Capraro; Hans-Georg (Rheinfelden, CH), Lang; Marc (Mulhouse, FR), Khanna; Satish Chandra (Bottmingen, CH)
Assignee: Novartis Finance Corporation (Summit, NJ)
Application Number:08/831,630
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers SquibbREYATAZatazanavir sulfateCAPSULE;ORAL021567-001Jun 20, 2003DISCNYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbREYATAZatazanavir sulfateCAPSULE;ORAL021567-002Jun 20, 2003ABRXYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbREYATAZatazanavir sulfateCAPSULE;ORAL021567-003Jun 20, 2003ABRXYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbREYATAZatazanavir sulfateCAPSULE;ORAL021567-004Oct 16, 2006ABRXYesYes► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbREYATAZatazanavir sulfatePOWDER;ORAL206352-001Jun 2, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Bristol-myers SquibbEVOTAZatazanavir sulfate; cobicistatTABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,849,911

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1018/96Apr 22, 1996
Switzerland0223/97Jan 31, 1997

Non-Orange Book Patents for Patent: 5,849,911

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
6,300,519 Antivirally active heterocyclic azahexane derivatives► Subscribe
6,166,004 Combinations of HIV protease inhibitors with reverse transcriptase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,849,911

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan409125► Subscribe
Slovakia285048► Subscribe
Slovakia145298► Subscribe
Slovenia0900210► Subscribe
Portugal900210► Subscribe
Poland193822► Subscribe
Poland329177► Subscribe
New Zealand509046► Subscribe
New Zealand509045► Subscribe
New Zealand332118► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Novartis
Johnson and Johnson
QuintilesIMS
Mallinckrodt
Express Scripts
Colorcon
Medtronic
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot